Raymond James Financial Inc. Purchases Shares of 110,460 uniQure (NASDAQ:QURE)

Raymond James Financial Inc. acquired a new position in uniQure (NASDAQ:QURE) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 110,460 shares of the biotechnology company’s stock, valued at approximately $1,951,000. Raymond James Financial Inc. owned approximately 0.23% of uniQure as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of QURE. RTW Investments LP acquired a new stake in uniQure during the third quarter valued at approximately $49,000. Quarry LP bought a new position in shares of uniQure in the third quarter valued at $58,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of uniQure during the 3rd quarter valued at $69,000. FNY Investment Advisers LLC bought a new stake in shares of uniQure during the 4th quarter worth $88,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of uniQure by 9.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock worth $195,000 after acquiring an additional 969 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Wells Fargo & Company reduced their target price on uniQure from $35.00 to $30.00 and set an “equal weight” rating for the company in a report on Friday, February 28th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $24.00 price objective on shares of uniQure in a research note on Tuesday, January 21st. Raymond James raised shares of uniQure from an “outperform” rating to a “strong-buy” rating and lifted their target price for the stock from $20.00 to $52.00 in a research report on Tuesday, December 10th. Cantor Fitzgerald upped their price target on shares of uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research report on Tuesday, December 10th. Finally, StockNews.com upgraded shares of uniQure to a “sell” rating in a research report on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, uniQure currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.89.

Insider Buying and Selling

In other news, CEO Matthew C. Kapusta sold 6,717 shares of the firm’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total transaction of $76,036.44. Following the transaction, the chief executive officer now owns 580,795 shares in the company, valued at approximately $6,574,599.40. This trade represents a 1.14 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Christian Klemt sold 2,916 shares of the company’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $11.32, for a total transaction of $33,009.12. Following the completion of the sale, the chief financial officer now owns 155,168 shares of the company’s stock, valued at $1,756,501.76. This represents a 1.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 90,830 shares of company stock worth $961,401. Corporate insiders own 4.74% of the company’s stock.

uniQure Trading Down 15.0 %

Shares of NASDAQ:QURE opened at $10.60 on Tuesday. The firm has a fifty day moving average of $13.70 and a two-hundred day moving average of $10.86. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 12-month low of $3.73 and a 12-month high of $19.18. The firm has a market capitalization of $573.22 million, a P/E ratio of -2.14 and a beta of 0.36.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.